Literature DB >> 3036639

Ricinus communis agglutinin II-reactive glycoproteins from the ascites of patients with hepatocellular carcinoma and their use in enzyme-linked immunosorbent assay.

M Fukushima, T Arima, H Nagashima.   

Abstract

Ricinus communis agglutinin II-reactive glycoproteins from the ascites of patients with hepatocellular carcinoma were prepared using lectin affinity chromatography. Normal serum- and cirrhotic ascites-components were removed by columns with immobilized antibodies against them. Ricinus communis agglutinin II-reactive glycoproteins thus obtained were supposed to be hepatocellular carcinoma-associated and less than 0.1% of the protein in the starting material. Polyacrylamide gel electrophoresis of these glycoproteins revealed more than 10 major polypeptides with molecular weights ranging from 20K to 200K daltons. The rabbit antiserum raised against them reacted with at least three components of 45, 52 and 55K daltons. The serum level of this antibody-reactive glycoproteins was assessed by an enzyme-linked immunosorbent assay. It was elevated in 91% of cases of hepatocellular carcinoma, 70% of cases of other gastrointestinal carcinoma, 88% of cases of liver cirrhosis, 55% of cases of chronic hepatitis, and 25% of cases of acute hepatitis. The mean value of hepatocellular carcinoma was significantly greater than those of other groups. These results suggest that some of Ricinus communis agglutinin II-reactive glycoproteins in hepatocellular carcinoma patients may be cancer-associated glycoproteins and that their serum levels are increased in hepatocellular carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036639     DOI: 10.1007/BF02774218

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  23 in total

1.  Serum glycoproteins in the liver diseases. III. Desialylated glycoproteins in the acute hepatitis.

Authors:  T Arima; Y Motoyama; T Yamamoto; K Nagata; T Kondo
Journal:  Gastroenterol Jpn       Date:  1977

2.  An abnormal membrane glycoprotein associated with malignancy in a wide range of different tumours.

Authors:  M E Bramwell; H Harris
Journal:  Proc R Soc Lond B Biol Sci       Date:  1978-04-13

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  A monoclonal antibody specific for the Thomsen-Friedenreich cryptic T antigen.

Authors:  A F Rahman; B M Longenecker
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

5.  Preparation and properties of a glycoprotein associated with malignancy.

Authors:  S D Bolmer; E A Davidson
Journal:  Biochemistry       Date:  1981-03-03       Impact factor: 3.162

6.  Structural determinants of Ricinus communis agglutinin and toxin specificity for oligosaccharides.

Authors:  J U Baenziger; D Fiete
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

7.  Glycoproteins and human cancer: II. Correlation between circulating level and disease status.

Authors:  H A Harvey; A Lipton; D White; E Davidson
Journal:  Cancer       Date:  1981-01-15       Impact factor: 6.860

8.  Serum glycoproteins in the liver diseases. V. Desialylated glycoproteins in chronic hepatitis.

Authors:  T Arima; Y Motoyama; T Yamamoto; K Nagata; T Kondo; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1978

9.  Hyperasialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma. Asialoglycoprotein receptor in cirrhosis and liver cell carcinoma.

Authors:  T Sawamura; H Nakada; H Hazama; Y Shiozaki; Y Sameshima; Y Tashiro
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

10.  Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen.

Authors:  S Hirohashi; H Clausen; T Yamada; Y Shimosato; S Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.